Lupin Ltd (LUPIN) – Strategy, SWOT and Corporate Finance Report

Lupin Ltd (LUPIN) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Lupin Ltd (Lupin) develops and manufactures generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It has expertise in the areas of cardiovascular, asthma, diabetic management, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB, and cephalosporins. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, diabetes, tuberculosis, inflammation and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries operates manufacturing facilities in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Scope

• Detailed information on Lupin Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Lupin Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Lupin Ltd including a breakdown and examination of key business segments

• News about Lupin Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Lupin Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Lupin Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Lupin Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Aarti Drugs Ltd

Abbott India Ltd

Cipla Ltd

Divi's Laboratories Ltd

Dr. Reddy's Laboratories Ltd

Intas Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr. Reddy's Laboratories Ltd

Cipla Ltd

Abbott India Ltd

Sun Pharmaceutical Industries Ltd

Lincoln Pharmaceuticals Ltd

Divi's Laboratories Ltd

Intas Pharmaceuticals Ltd

Aarti Drugs Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Lupin Ltd - Key Facts

Lupin Ltd - Key Employees

Lupin Ltd - Key Employee Biographies

Lupin Ltd - Major Products and Services

Lupin Ltd - History

Lupin Ltd - Company Statement

Lupin Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Lupin Ltd - Business Description

Geographical Segment: India

Performance

Geographical Segment: Others

Performance

Geographical Segment: The United States

Performance

R&D Overview

Lupin Ltd - Corporate Strategy

Lupin Ltd - SWOT Analysis

SWOT Analysis - Overview

Lupin Ltd - Strengths

Lupin Ltd - Weaknesses

Lupin Ltd - Opportunities

Lupin Ltd - Threats

Lupin Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Lupin Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Aug 14, 2023: Lupin’s Mandideep Unit-2 Facility Completes U.S. FDA Inspection With No Observations

Aug 03, 2023: Lupin Announces Q1 FY2024 Results

Aug 03, 2023: Lupin Q1 FY2024 Results

Jul 28, 2023: Lupin Foundation Strengthens Lives Program With Its First Mobile Medical Van ; Flag-off by Health Minister, Government of Rajasthan

Jul 27, 2023: Lupin Announces Resolution of USFDA Warning Letter for Its GOA and Pithampur Facilities

Jul 26, 2023: Lupin : Disclosure Pursuant to Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015

Jul 12, 2023: Lupin Announces Annual Report for the year ended March 31, 2023

Jul 12, 2023: Lupin Notice of 41st Annual General Meeting

Jul 12, 2023: LUPIN: U.S. FDA Inspection of the Company’s Nagpur Oral Solid Dosage Facility

Jul 11, 2023: Lupin Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Lupin Ltd, Key Facts

Lupin Ltd, Key Employees

Lupin Ltd, Key Employee Biographies

Lupin Ltd, Major Products and Services

Lupin Ltd, History

Lupin Ltd, Other Locations

Lupin Ltd, Subsidiaries

Lupin Ltd, Joint Venture

Lupin Ltd, Key Competitors

Lupin Ltd, Ratios based on current share price

Lupin Ltd, Annual Ratios

Lupin Ltd, Annual Ratios (Cont…1)

Lupin Ltd, Annual Ratios (Cont…2)

Lupin Ltd, Interim Ratios

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Lupin Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Lupin Ltd, Performance Chart (2019 – 2023)

Lupin Ltd, Ratio Charts

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports